Q1 2025 net profit rose 2.1% year-over-year to ₩635.3 billion, driven by strong health segment growth and investment gains. K-ICS ratio remains robust at 180%, with a focus on high-margin health products and a progressive move toward a 50% payout ratio.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.